Trial(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Trial details
- Registry ID
- NCT05907954
- Phase
- Phase 2
IDYA
IDEAYA Biosciences
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaNCT05907954 | IDEAYA Biosciences | Phase 2 | Active not recruiting | 2027-04-30Estimated |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332 | IDEAYA Biosciences | Phase 2, Phase 3 | Active not recruiting | 2027-01-15Estimated |
| Neoadjuvant Darovasertib in Primary Uveal MelanomaNCT07015190 | IDEAYA Biosciences | Phase 3 | Recruiting | 2030-10Estimated |
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Trial details
- Registry ID
- NCT05987332
- Phase
- Phase 2, Phase 3
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Trial details
- Registry ID
- NCT07015190
- Phase
- Phase 3
Latest recorded trial changes
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NCT05907954 · IDEAYA Biosciences
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332 · IDEAYA Biosciences
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Progression-Free Survival (PFS) by blinded independent central review (BICR) of IDE196 + Crizotinib compared to investigator's choice of treatment
Measure: Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment
+ After
Measure: Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: Measure: Phase 2 Progression-Free Survival (PFS) Measure: Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NCT05907954 · IDEAYA Biosciences
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Incidence of Adverse Events (AEs) and significant laboratory abnormalities Measure: Cohort 1 (enucleation): Number of patients converted from requiring enucleation to radiation Measure: Cohort 2 (plaque brachytherapy): Estimated change in modeled radiation dose
+ After
Measure: Incidence of Adverse Events (AEs) and significant laboratory abnormalities Measure: Cohort 1 (enucleation): Number of patients converted from requiring enucleation to radiation Measure: Cohort 2 (plaque brachytherapy): Estimated change in modeled radiation dose Measure: Cohort 3 (patients with small UM tumors): Number of patients with clinical benefit per protocol-defined UM response criteria
Planned enrollment increased by 78 participants
− Before
82 participants (planned)
+ After
160 participants (planned)
Primary completion date changed
− Before
31 Jan 2026
+ After
30 Apr 2027